Feldan News

MONTREAL, April 18, 2023 – CQDM is proud to announce the funding of a project worth $503,779 aiming at optimizing a new drug delivery platform in the lungs to treat …

Feldan Therapeutics is pleased to share the promising results of FLD103 to treat basal cell carcinoma. A poster presented at the WCH23 Dermatology Conference last January (Intralesional Treatment of Basal …

Quebec City, Canada, January 18, 2022 - Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced today it was awarded funding by the …

Read more on pages 54 to 57: BIOTECanada Insights sping 2021 …

Congratulations to the team at NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program for publishing their work in the journal Nature. Feldan is honoured to be part of this …

Québec, Canada, February 9, 2021 – Feldan Therapeutics, a biotechnology company that develops therapeutics based on the intracellular delivery of proteins and peptides, announces the appointment of Dr. David J …

Quebec City, Canada, January 14, 2021 – Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on the intracellular delivery of proteins and peptides, announces the creation …

Quebec City, Canada, June 16, 2020, Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on its intracellular delivery technology, today announced the appointment of Dr. Robert …

Dr. Paul McCray (University of Iowa) and Feldan Therapeutics enable protein and CRISPR nuclease delivery to cultured human well-differentiated airway epithelial cells and in vivo using the Feldan Shuttle technology …

On June 13th 2019, Anges Québec celebrated its 10th anniversary as part of the annual Rendez-vous 2019, the event that brings together angel investors, portfolio companies, venture capital ecosystem players …